Free Trial
NASDAQ:SMMT

Summit Therapeutics (SMMT) Stock Price, News & Analysis

Summit Therapeutics logo
$21.43 +0.56 (+2.68%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$21.35 -0.08 (-0.37%)
As of 10/3/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Summit Therapeutics Stock (NASDAQ:SMMT)

Advanced

Key Stats

Today's Range
$20.48
$21.49
50-Day Range
$17.60
$29.32
52-Week Range
$15.55
$36.91
Volume
2.24 million shs
Average Volume
5.64 million shs
Market Capitalization
$15.92 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.29
Consensus Rating
Hold

Company Overview

Summit Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

SMMT MarketRank™: 

Summit Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 415th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Summit Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 11 buy ratings, 1 hold rating, and 5 sell ratings.

  • Upside Potential

    Summit Therapeutics has a consensus price target of $31.29, representing about 46.0% upside from its current price of $21.43.

  • Amount of Analyst Coverage

    Summit Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Summit Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Summit Therapeutics are expected to decrease in the coming year, from ($0.30) to ($0.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Summit Therapeutics is -21.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Summit Therapeutics is -21.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Summit Therapeutics has a P/B Ratio of 40.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Summit Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    4.34% of the outstanding shares of Summit Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Summit Therapeutics has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in Summit Therapeutics has recently increased by 8.38%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Summit Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Summit Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.34% of the outstanding shares of Summit Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Summit Therapeutics has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in Summit Therapeutics has recently increased by 8.38%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Summit Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Summit Therapeutics this week, compared to 9 articles on an average week.
  • Search Interest

    84 people have searched for SMMT on MarketBeat in the last 30 days. This is an increase of 236% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Summit Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Summit Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $11,969,512.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    84.90% of the stock of Summit Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 4.61% of the stock of Summit Therapeutics is held by institutions.

  • Read more about Summit Therapeutics' insider trading history.
Receive SMMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SMMT Stock News Headlines

URGENT: The Market's 3 Red Flags Are Flashing
The warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed.tc pixel
1 Monster Stock in the Making to Buy and Hold
See More Headlines

SMMT Stock Analysis - Frequently Asked Questions

Summit Therapeutics' stock was trading at $17.84 on January 1st, 2025. Since then, SMMT stock has increased by 20.1% and is now trading at $21.43.

Summit Therapeutics PLC (NASDAQ:SMMT) announced its quarterly earnings results on Monday, August, 11th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.66.

Summit Therapeutics (SMMT) raised $40 million in an initial public offering on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.

Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Summit Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
8/11/2025
Today
10/05/2025
Next Earnings (Estimated)
10/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SMMT
CIK
1599298
Employees
110
Year Founded
2003

Price Target and Rating

High Price Target
$50.00
Low Price Target
$12.00
Potential Upside/Downside
+46.0%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
18 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$221.32 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-208.64%
Return on Assets
-181.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.13
Quick Ratio
5.13

Sales & Book Value

Annual Sales
$700 thousand
Price / Sales
22,741.82
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.53 per share
Price / Book
40.43

Miscellaneous

Outstanding Shares
742,850,000
Free Float
112,170,000
Market Cap
$15.92 billion
Optionable
Optionable
Beta
-1.13

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:SMMT) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners